GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery-Reference-Cited by-同舟云学术

GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery

Published:2021-04-10 Issue:8 Volume:64 Page:4312-4332
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Carullo Gabriele¹^ORCID,Mazzotta Sarah²^ORCID,Vega-Holm Margarita³^ORCID,Iglesias-Guerra Fernando³,Vega-Pérez José Manuel³,Aiello Francesca⁴^ORCID,Brizzi Antonella¹

Affiliation:

1. Department of Biotechnology, Chemistry, and Pharmacy, DoE 2018-2022, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy

2. Department of Pharmaceutical Sciences, University of Milan, Via Luigi Mangiagalli 25, 20133 Milano, Italy

3. Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Seville, Profesor García González 2, 41012 Seville, Spain

4. Department of Pharmacy, Health and Nutritional Sciences, DoE 2018-2022, University of Calabria, Edificio Polifunzionale, 87036 Rende, Cosenza, Italy

Funder

Ministero dell’Istruzione, dell’Università e della Ricerca

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01002

Reference140 articles.

1. Trends in incidence of total or type 2 diabetes: systematic review

2. Empagliflozin in the treatment of type 2 diabetes: evidence to date

3. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020